{"id":"ym178","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, YM178 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.","oneSentence":"YM178 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:01.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT05713799","phase":"PHASE2","title":"Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Insulin Resistance, Obesity","enrollment":60},{"nctId":"NCT05621616","phase":"PHASE3","title":"A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-02-28","conditions":"Neurogenic Detrusor Overactivity","enrollment":7},{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT07447518","phase":"EARLY_PHASE1","title":"Double j Stent Related Symptoms","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-09-22","conditions":"Lower Urinary Tract Symptoms","enrollment":535},{"nctId":"NCT07398261","phase":"PHASE3","title":"Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Menoufia University","startDate":"2023-08-28","conditions":"Treatment of Non-monosymptomatic Nocturnal Enuresis","enrollment":151},{"nctId":"NCT07305298","phase":"","title":"Mirabegron in Patients With Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"University of Naples","startDate":"2026-04-01","conditions":"Dry AMD, Overactive Bladder","enrollment":312},{"nctId":"NCT05051436","phase":"PHASE4","title":"The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2021-12-13","conditions":"Pre-diabetes, Obesity","enrollment":96},{"nctId":"NCT04666636","phase":"PHASE2","title":"Mechanisms for Activation of Beige Adipose Tissue in Humans","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2020-12-07","conditions":"PreDiabetes","enrollment":65},{"nctId":"NCT07259148","phase":"NA","title":"Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emilio José Dávila Álvarez","startDate":"2025-11-22","conditions":"Urgency Urinary Incontinence","enrollment":80},{"nctId":"NCT07337252","phase":"","title":"Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-01","conditions":"Overactive Bladder","enrollment":61},{"nctId":"NCT07187466","phase":"PHASE4","title":"Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Overactive Bladder, Parkinson Disease","enrollment":146},{"nctId":"NCT07310797","phase":"PHASE4","title":"Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion","status":"NOT_YET_RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2026-01-01","conditions":"Ureteral Calculi","enrollment":500},{"nctId":"NCT07307261","phase":"NA","title":"Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Avraiem Talaat","startDate":"2024-10-10","conditions":"Ureteric Stent-related Morbidity","enrollment":300},{"nctId":"NCT07261683","phase":"PHASE2","title":"Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-12","conditions":"Ovarian Cancer, Immunotherapy, Pembrolizumab","enrollment":20},{"nctId":"NCT06465576","phase":"PHASE4","title":"Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-05-27","conditions":"Urinary Incontinence in Children","enrollment":216},{"nctId":"NCT06551246","phase":"PHASE3","title":"Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-06-27","conditions":"Urinary Incontinence in Children","enrollment":236},{"nctId":"NCT06110975","phase":"NA","title":"Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne Estrup Olesen","startDate":"2023-12-01","conditions":"Overactive Bladder, Deprescribing, PIMS","enrollment":72},{"nctId":"NCT05880862","phase":"EARLY_PHASE1","title":"Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2023-09-28","conditions":"Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls","enrollment":48},{"nctId":"NCT07199894","phase":"PHASE3","title":"Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-12-01","conditions":"Nocturnal Enuresis in Children","enrollment":120},{"nctId":"NCT05806164","phase":"PHASE4","title":"Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2023-06-06","conditions":"Urgency Urinary Incontinence","enrollment":432},{"nctId":"NCT06803030","phase":"PHASE3","title":"Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms","status":"RECRUITING","sponsor":"Bir Hospital","startDate":"2025-08-30","conditions":"Ureteral Stent-Related Symptom","enrollment":189},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":"Urinary Bladder, Overactive","enrollment":220},{"nctId":"NCT06133075","phase":"PHASE2","title":"Using Mirabegron to Increase BP in Patients With POTS","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-12-22","conditions":"Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope","enrollment":20},{"nctId":"NCT05990387","phase":"PHASE1, PHASE2","title":"MIrabegron and Physiological Function in Cold Environments","status":"COMPLETED","sponsor":"Indiana University","startDate":"2023-07-19","conditions":"Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue","enrollment":17},{"nctId":"NCT07025642","phase":"NA","title":"Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes","status":"RECRUITING","sponsor":"Mackay Medical College","startDate":"2025-07-01","conditions":"Overactive Bladder (OAB)","enrollment":60},{"nctId":"NCT07018934","phase":"","title":"Alfuzosin and Mirabegron for Double-J Stent Symptoms","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-06-01","conditions":"Ureteral Stent-Related Symptoms","enrollment":100},{"nctId":"NCT07017439","phase":"PHASE3","title":"Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","startDate":"2025-08","conditions":"Benign Prostate Hypertrophy(BPH)","enrollment":50},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT05369351","phase":"PHASE2","title":"Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-01-17","conditions":"Intracerebral Haemorrhage","enrollment":25},{"nctId":"NCT05604222","phase":"PHASE4","title":"Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women","status":"RECRUITING","sponsor":"Shachi Tyagi","startDate":"2023-03-05","conditions":"Urgency Urinary Incontinence, Nocturia","enrollment":120},{"nctId":"NCT05968885","phase":"PHASE4","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2021-10-01","conditions":"Urinary Bladder, Overactive, Urodynamics, Effect of Drug","enrollment":300},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT06791460","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-03-18","conditions":"Ovarian Cancer Recurrent","enrollment":296},{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":"Interstitial Cystitis","enrollment":26},{"nctId":"NCT02599480","phase":"PHASE2","title":"Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure","status":"COMPLETED","sponsor":"Jean-Luc Balligand","startDate":"2016-09-12","conditions":"Hypertrophy, Left Ventricular","enrollment":296},{"nctId":"NCT05067478","phase":"","title":"Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2021-10-28","conditions":"Overactive Bladder","enrollment":403},{"nctId":"NCT04823442","phase":"NA","title":"Activation of Brown Adipose Tissue Metabolism Using Mirabegron","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-01-21","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT02216214","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-10-07","conditions":"Overactive Bladder (OAB)","enrollment":888},{"nctId":"NCT01638000","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-06-12","conditions":"Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases","enrollment":1887},{"nctId":"NCT00912964","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2030},{"nctId":"NCT00662909","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-28","conditions":"Urinary Bladder, Overactive","enrollment":2149},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2336},{"nctId":"NCT04562090","phase":"PHASE4","title":"A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2021-01-06","conditions":"Urge Incontinence, Overactive Bladder (OAB)","enrollment":249},{"nctId":"NCT04641975","phase":"PHASE3","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-03-15","conditions":"Overactive Bladder (OAB), Pharmacokinetics of Mirabegron","enrollment":26},{"nctId":"NCT02656173","phase":"PHASE4","title":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-01-25","conditions":"Overactive Bladder","enrollment":568},{"nctId":"NCT02751931","phase":"PHASE3","title":"Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-06-17","conditions":"Neurogenic Detrusor Overactivity","enrollment":91},{"nctId":"NCT04501640","phase":"PHASE4","title":"A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2020-09-21","conditions":"Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects","enrollment":24},{"nctId":"NCT02757768","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-06-13","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":715},{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":"Overactive Bladder (OAB)","enrollment":649},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT02526979","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-12-17","conditions":"Overactive Bladder, Neurogenic Detrusor Overactivity","enrollment":9},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT01604928","phase":"PHASE2","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2004-04-05","conditions":"Urinary Bladder, Overactive","enrollment":260},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence","enrollment":1829},{"nctId":"NCT00527033","phase":"PHASE2","title":"A Study of YM178 in Patients With Symptomatic Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-09-11","conditions":"Urinary Bladder, Overactive","enrollment":842},{"nctId":"NCT02320773","phase":"","title":"A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-25","conditions":"Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder","enrollment":863},{"nctId":"NCT00966004","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07-24","conditions":"Urinary Bladder, Overactive","enrollment":1139},{"nctId":"NCT01043666","phase":"PHASE3","title":"A Study of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-21","conditions":"Urinary Bladder, Overactive","enrollment":1126},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT02211846","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-09-21","conditions":"Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron","enrollment":34},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":"Overactive Bladder (OAB)","enrollment":5589},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT00940121","phase":"PHASE1","title":"Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-30","conditions":"Healthy, Pharmacokinetics of Mirabegron","enrollment":91},{"nctId":"NCT01950520","phase":"PHASE2","title":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-07","conditions":"Healthy Volunteers","enrollment":47},{"nctId":"NCT05634174","phase":"PHASE1","title":"ADRB3 Signaling Pathway in Human Adipose Tissue","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-08-01","conditions":"Obesity, Prediabetes","enrollment":40},{"nctId":"NCT02893553","phase":"PHASE2","title":"The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2016-12","conditions":"Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity","enrollment":21},{"nctId":"NCT05221021","phase":"PHASE4","title":"Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2022-10-01","conditions":"Overactive Bladder Syndrome","enrollment":152},{"nctId":"NCT06534762","phase":"PHASE2","title":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-07-15","conditions":"NSCLC, SCLC, Colorectal Cancer","enrollment":260},{"nctId":"NCT04766021","phase":"PHASE1, PHASE2","title":"Mirabegron and Physiological Function in Cold Environments","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-11-30","conditions":"Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue","enrollment":30},{"nctId":"NCT06011265","phase":"EARLY_PHASE1","title":"Does Mirabegron Increase the Body Heat Generated by the Nervous System","status":"COMPLETED","sponsor":"Christopher Bell","startDate":"2023-04-27","conditions":"Thermoregulation","enrollment":19},{"nctId":"NCT03106623","phase":"PHASE2","title":"Study of ONO-8577 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-04-07","conditions":"Overactive Bladder","enrollment":207},{"nctId":"NCT06184334","phase":"NA","title":"Management of OAB in Female Patients .","status":"COMPLETED","sponsor":"Elsayed Abdelhalim Elsayed","startDate":"2022-09-14","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT06181591","phase":"PHASE2","title":"A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-04-01","conditions":"Overactive Bladder","enrollment":44},{"nctId":"NCT03817931","phase":"PHASE4","title":"Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-05","conditions":"Overactive Bladder, Dementia, Lower Urinary Tract Symptoms","enrollment":12},{"nctId":"NCT05992428","phase":"PHASE1","title":"Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-08-22","conditions":"Healthy","enrollment":37},{"nctId":"NCT06181019","phase":"PHASE1","title":"Acupuncture Combined With Mirabegron in the Treatment of OAB","status":"UNKNOWN","sponsor":"The Affiliated Ganzhou Hospital of Nanchang University","startDate":"2021-12-01","conditions":"Overactive Bladder","enrollment":75},{"nctId":"NCT06124066","phase":"PHASE4","title":"THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2022-07-01","conditions":"Ureteral Stone, Kidney Stones, Ureteral Stenosis","enrollment":42},{"nctId":"NCT06123364","phase":"NA","title":"Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Serdinsek Tamara","startDate":"2019-10-14","conditions":"Overactive Bladder, Overactive Bladder Syndrome","enrollment":56},{"nctId":"NCT02086188","phase":"PHASE4","title":"Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis","status":"COMPLETED","sponsor":"Theodore R. Brown, MD MPH","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":28},{"nctId":"NCT04023253","phase":"PHASE3","title":"Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2019-08-01","conditions":"Overactive Bladder Syndrome","enrollment":120},{"nctId":"NCT05946902","phase":"PHASE4","title":"Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2023-09-12","conditions":"Female Patients With Overactive Bladder Syndrome","enrollment":150},{"nctId":"NCT05617664","phase":"NA","title":"Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-11-23","conditions":"Nocturnal Enuresis","enrollment":150},{"nctId":"NCT04907032","phase":"PHASE4","title":"Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-10-01","conditions":"Overactive Bladder","enrollment":54},{"nctId":"NCT02462837","phase":"PHASE2","title":"Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2015-05","conditions":"Urinary Bladder, Overactive, Pain, Lower Urinary Tract Symptoms","enrollment":11},{"nctId":"NCT03251300","phase":"PHASE4","title":"Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2017-08-01","conditions":"Overactive Bladder Syndrome","enrollment":120},{"nctId":"NCT05040984","phase":"","title":"Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2021-04-30","conditions":"Overactive Bladder Syndrome","enrollment":500},{"nctId":"NCT02540707","phase":"PHASE4","title":"Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-09-08","conditions":"Overactive Bladder Syndrome","enrollment":113},{"nctId":"NCT05779514","phase":"NA","title":"Effect of Mirabegron on Promoting Brown Adipose Tissue Activation","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2022-08-18","conditions":"Tumour","enrollment":20},{"nctId":"NCT05767632","phase":"PHASE1","title":"Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-05-30","conditions":"Healthy","enrollment":30},{"nctId":"NCT05745584","phase":"NA","title":"Effect of Mirabegron on Bladder Compliance","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-01-12","conditions":"Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics","enrollment":15},{"nctId":"NCT05668715","phase":"NA","title":"Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder","status":"UNKNOWN","sponsor":"Pamukkale University","startDate":"2023-01-01","conditions":"Urinary Bladder, Overactive","enrollment":40},{"nctId":"NCT02095665","phase":"PHASE4","title":"Ureteral Stent-related Pain and Mirabegron (SPAM) Trial","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2014-01-01","conditions":"Nephrolithiasis","enrollment":22},{"nctId":"NCT05416450","phase":"NA","title":"The Efficacy of Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder","status":"UNKNOWN","sponsor":"Pamukkale University","startDate":"2022-07-01","conditions":"Urinary Bladder, Overactive","enrollment":48},{"nctId":"NCT04420533","phase":"NA","title":"Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-06-05","conditions":"Urinary Bladder, Overactive, Sexual Behavior, Sexual Activity","enrollment":150},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT05452434","phase":"PHASE4","title":"Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-15","conditions":"Overactive Bladder","enrollment":600},{"nctId":"NCT03087578","phase":"NA","title":"Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2017-07-01","conditions":"Overactive Bladder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HEADACHE"},{"count":2,"reaction":"ARTHRALGIA"},{"count":2,"reaction":"CONFUSIONAL STATE"},{"count":2,"reaction":"EXTRASYSTOLES"},{"count":2,"reaction":"HYPERTENSION"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PALPITATIONS"},{"count":2,"reaction":"VISION BLURRED"},{"count":1,"reaction":"ACTIVITIES OF DAILY LIVING IMPAIRED"},{"count":1,"reaction":"ANGINA PECTORIS"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mirabegron","Mirabegron"],"phase":"phase_3","status":"active","brandName":"YM178","genericName":"YM178","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YM178 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}